Exploring Plausible Therapeutic Targets for Alzheimer's Disease using Multi-omics Approach, Machine Learning and Docking

Muddapu, V.R.; Dharshini, S.A.P.; Chakravarthy, V.S.; Gromiha, M.M. Neurodegenerative diseases – Is metabolic deficiency the root cause? Front. Neurosci., 2020, 14, 213.
[http://dx.doi.org/10.3389/fnins.2020.00213 ] [PMID: 32296300]

Wilde, G.J.C.; Pringle, A.K.; Wright, P.; Iannotti, F. Differential vulnerability of the CA1 and CA3 subfields of the hippocampus to superoxide and hydroxyl radicals in vitro. J. Neurochem., 1997, 69(2), 883-886.
[http://dx.doi.org/10.1046/j.1471-4159.1997.69020883.x ] [PMID: 9231752]

Pissadaki, E.K.; Bolam, J.P. The energy cost of action potential propagation in dopamine neurons: Clues to susceptibility in Parkinson’s disease. Front. Comput. Neurosci., 2013, 7, 13.
[http://dx.doi.org/10.3389/fncom.2013.00013 ] [PMID: 23515615]

Bolam, J.P.; Pissadaki, E.K. Living on the edge with too many mouths to feed: Why dopamine neurons die. Mov. Disord., 2012, 27(12), 1478-1483.
[http://dx.doi.org/10.1002/mds.25135 ] [PMID: 23008164]

Pacelli, C.; Giguère, N.; Bourque, M.J.; Lévesque, M.; Slack, R.S.; Trudeau, L.É. Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons. Curr. Biol., 2015, 25(18), 2349-2360.
[http://dx.doi.org/10.1016/j.cub.2015.07.050 ] [PMID: 26320949]

Carriedo, S.G.; Sensi, S.L.; Yin, H.Z.; Weiss, J.H. AMPA exposures induce mitochondrial Ca2+ overload and ROS generation in spinal motor neurons in vitro. J. Neurosci., 2000, 20(1), 240-250.
[http://dx.doi.org/10.1523/JNEUROSCI.20-01-00240.2000 ] [PMID: 10627601]

Dharshini, S.A.P.; Taguchi, Y.; Gromiha, M.M. Investigating the energy crisis in Alzheimer’s disease using transcriptome study. Sci. Rep., 2019, 9(1), 18509.
[http://dx.doi.org/10.1038/s41598-019-54782-y ] [PMID: 31811163]

Patel, A.B.; Tiwari, V.; Veeraiah, P.; Saba, K. Increased astroglial activity and reduced neuronal function across brain in AβPP-PS1 mouse model of Alzheimer’s disease. J. Cereb. Blood Flow Metab., 2018, 38(7), 1213-1226.
[http://dx.doi.org/10.1177/0271678X17709463 ] [PMID: 28585882]

Miyazaki, K.; Ohta, Y.; Nagai, M.; Morimoto, N.; Kurata, T.; Takehisa, Y.; Ikeda, Y.; Matsuura, T.; Abe, K. Disruption of neurovascular unit prior to motor neuron degeneration in amyotrophic lateral sclerosis. J. Neurosci. Res., 2011, 89(5), 718-728.
[http://dx.doi.org/10.1002/jnr.22594 ] [PMID: 21337372]

Zhu, X.; Smith, M.A.; Honda, K.; Aliev, G.; Moreira, P.I.; Nunomura, A.; Casadesus, G.; Harris, P.L.R.; Siedlak, S.L.; Perry, G. Vascular oxidative stress in Alzheimer disease. J. Neurol. Sci., 2007, 257(1-2), 240-246.
[http://dx.doi.org/10.1016/j.jns.2007.01.039 ] [PMID: 17337008]

Chen, X.; Pan, W. The treatment strategies for neurodegenerative diseases by integrative medicine. Integr. Med. Int., 2015, 1(4), 223-225.
[http://dx.doi.org/10.1159/000381546]

Durães, F.; Pinto, M.; Sousa, E. Old drugs as new treatments for neurodegenerative diseases. Pharmaceuticals, 2018, 11(2), 44.
[http://dx.doi.org/10.3390/ph11020044 ] [PMID: 29751602]

Cummings, J.; Lee, G.; Zhong, K.; Fonseca, J.; Taghva, K. Alzheimer’s disease drug development pipeline: 2021. Alzheimers Dement., 2021, 7(1), e12179.
[http://dx.doi.org/10.1002/trc2.12179 ] [PMID: 34095440]

Ahmad, F.; Singh, K.; Das, D.; Gowaikar, R.; Shaw, E.; Ramachandran, A.; Rupanagudi, K.V.; Kommaddi, R.P.; Bennett, D.A.; Ravindranath, V. Reactive oxygen species-mediated loss of synaptic akt1 signaling leads to deficient activity-dependent protein translation early in Alzheimer’s disease. Antioxid. Redox Signal., 2017, 27(16), 1269-1280.
[http://dx.doi.org/10.1089/ars.2016.6860 ] [PMID: 28264587]

Llorens-MartÃn, M.; Blazquez-Llorca, L.; Benavides, P.R.; Rabano, A.; Hernandez, F.; Avila, J.; DeFelipe, J. Selective alterations of neurons and circuits related to early memory loss in Alzheimer’s disease. Front. Neuroanat., 2014, 8, 38.

Liu, C.C.; Kanekiyo, T.; Xu, H.; Bu, G.; Bu, G. Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat. Rev. Neurol., 2013, 9(2), 106-118.
[http://dx.doi.org/10.1038/nrneurol.2012.263 ] [PMID: 23296339]

Huang, Y. Roles of Apolipoprotein E4 (ApoE4) in the pathogenesis of Alzheimer’s disease: Lessons from ApoE mouse models. Biochem. Soc. Trans., 2011, 39(4), 924-932.
[http://dx.doi.org/10.1042/BST0390924 ] [PMID: 21787325]

Hung, S.Y.; Fu, W.M. Drug candidates in clinical trials for Alzheimer’s disease. J. Biomed. Sci., 2017, 24(1), 47.
[http://dx.doi.org/10.1186/s12929-017-0355-7 ] [PMID: 28720101]

Coultrap, S.J.; Nixon, K.M.; Alvestad, R.M.; Fernando Valenzuela, C.; Browning, M.D. Differential expression of NMDA receptor subunits and splice variants among the CA1, CA3 and dentate gyrus of the adult rat. Brain Res. Mol. Brain Res., 2005, 135(1-2), 104-111.
[http://dx.doi.org/10.1016/j.molbrainres.2004.12.005] [PMID: 15857673]

Liu, Z.; Lv, C.; Zhao, W.; Song, Y.; Pei, D.; Xu, T. NR2B-containing NMDA receptors expression and their relationship to apoptosis in hippocampus of Alzheimer’s disease-like rats. Neurochem. Res., 2012, 37(7), 1420-1427.
[http://dx.doi.org/10.1007/s11064-012-0726-0 ] [PMID: 22359056]

Mairet, C.G.; Courchet, J.; Pieraut, S.; Courchet, V.; Maximov, A.; Polleux, F. The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Aβ oligomers through Tau phosphorylation. Neuron, 2013, 78(1), 94-108.
[http://dx.doi.org/10.1016/j.neuron.2013.02.003 ] [PMID: 23583109]

Marcelo, K.L.; Means, A.R.; York, B. The Ca2+/calmodulin/] CaMKK2 Axis: Nature’s metabolic CaMshaft. Trends Endocrinol. Metab., 2016, 27(10), 706-718.
[http://dx.doi.org/10.1016/j.tem.2016.06.001 ] [PMID: 27449752]

Espeseth, A.S.; Huang, Q.; Gates, A.; Xu, M.; Yu, Y.; Simon, A.J.; Shi, X.P.; Zhang, X.; Hodor, P.; Stone, D.J.; Burchard, J.; Cavet, G.; Bartz, S.; Linsley, P.; Ray, W.J.; Hazuda, D. A genome wide analysis of ubiquitin ligases in APP processing identifies a novel regulator of BACE1 mRNA levels. Mol. Cell. Neurosci., 2006, 33(3), 227-235.
[http://dx.doi.org/10.1016/j.mcn.2006.07.003 ] [PMID: 16978875]

Perry, E.K.; Perry, R.H.; Tomlinson, B.E.; Blessed, G.; Gibson, P.H. Coenzyme a-acetylating enzymes in Alzheimer’s disease: Possible cholinergic ‘compartment’ of pyruvate dehydrogenase. Neurosci. Lett., 1980, 18(1), 105-110.
[http://dx.doi.org/10.1016/0304-3940(80)90220-7 ] [PMID: 6133246]

Wang, L.Y.; Shofer, J.B.; Rohde, K.; Hart, K.L.; Hoff, D.J.; McFall, Y.H.; Raskind, M.A.; Peskind, E.R. Prazosin for the treatment of behavioral symptoms in Alzhemier’s disease patents with agitataion and aggression. Am. J. Geriatr. Psychiatry, 2009, 17, 744.
[http://dx.doi.org/10.1097/JGP.0b013e3181ab8c61] [PMID: 19700947]

Dai, W.; Lopez, O.L.; Carmichael, O.T.; Becker, J.T.; Kuller, L.H.; Gach, H.M. Mild cognitive impairment and alzheimer disease: Patterns of altered cerebral blood flow at MR imaging. Radiology, 2009, 250(3), 856-866.
[http://dx.doi.org/10.1148/radiol.2503080751 ] [PMID: 19164119]

Craft, S. The role of metabolic disorders in Alzheimer disease and vascular dementia: Two roads converged. Arch. Neurol., 2009, 66(3), 300-305.
[http://dx.doi.org/10.1001/archneurol.2009.27 ] [PMID: 19273747]

Von Bernhardi, R.; Cornejo, F.; Parada, G.E.; Eugenín, J. Role of TGFβ signaling in the pathogenesis of Alzheimer’s disease. Front. Cell. Neurosci., 2015, 9, 426.
[http://dx.doi.org/10.3389/fncel.2015.00426 ] [PMID: 26578886]

Dharshini, S.A.P.; Jemimah, S.; Taguchi, Y.H.; Gromiha, M.M. Exploring common therapeutic targets for neurodegenerative disorders using transcriptome study. Front. Genet., 2021, 12, 639160.
[http://dx.doi.org/10.3389/fgene.2021.639160 ] [PMID: 33815473]

Coppedè, F. The potential of epigenetic therapies in neurodegenerative diseases. Front. Genet., 2014, 5, 220.
[http://dx.doi.org/10.3389/fgene.2014.00220 ] [PMID: 25071843]

Dokmanovic, M.; Clarke, C.; Marks, P.A. Histone deacetylase inhibitors: Overview and perspectives. Mol. Cancer Res., 2007, 5(10), 981-989.
[http://dx.doi.org/10.1158/1541-7786.MCR-07-0324] [PMID: 17951399]

Gratuze, M.; Leyns, C.E.G.; Holtzman, D.M. New insights into the role of TREM2 in Alzheimer’s disease. Mol. Neurodegener., 2018, 13(1), 66.
[http://dx.doi.org/10.1186/s13024-018-0298-9 ] [PMID: 30572908]

Kargbo, R.B. Sigma-1 and sigma-2 receptor modulators as potential therapeutics for Alzheimer’s Disease. ACS Med. Chem. Lett., 2021, 12(2), 178-179.
[http://dx.doi.org/10.1021/acsmedchemlett.1c00002] [PMID: 33603961]

Paes, D.; Lardenoije, R.; Carollo, R.M.; Roubroeks, J.A.Y.; Schepers, M.; Coleman, P.; Mastroeni, D.; Delvaux, E.; Pishva, E.; Lunnon, K.; Vanmierlo, T.; van den Hove, D.; Prickaerts, J. Increased isoform-specific phosphodiesterase 4D expression is associated with pathology and cognitive impairment in Alzheimer’s disease. Neurobiol. Aging, 2021, 97, 56-64.
[http://dx.doi.org/10.1016/j.neurobiolaging.2020.10.004] [PMID: 33157432]

Esterline, R.; Oscarsson, J.; Burns, J. A role for sodium glucose Cotransporter 2 Inhibitors (SGLT2is) in the treatment of Alzheimer’s disease? Int. Rev. Neurobiol., 2020, 155, 113-140.
[http://dx.doi.org/10.1016/bs.irn.2020.03.018 ] [PMID: 32854852]

Grubman, A.; Chew, G.; Ouyang, J.F.; Sun, G.; Choo, X.Y.; McLean, C.; Simmons, R.K.; Buckberry, S.; Vargas, L.D.B.; Poppe, D.; Pflueger, J.; Lister, R.; Rackham, O.J.L.; Petretto, E.; Polo, J.M. A single-cell atlas of entorhinal cortex from individuals with Alzheimer’s disease reveals cell-type-specific gene expression regulation. Nat. Neurosci., 2019, 22(12), 2087-2097.

Settembre, C.; Fraldi, A.; Medina, D.L.; Ballabio, A. Signals from the lysosome: A control centre for cellular clearance and energy metabolism. Nat. Rev. Mol. Cell Biol., 2013, 14(5), 283-296.
[http://dx.doi.org/10.1038/nrm3565 ] [PMID: 23609508]

Song, J.X.; Liu, J.; Jiang, Y.; Wang, Z.Y.; Li, M. Transcription factor EB: An emerging drug target for neurodegenerative disorders. Drug Discov. Today, 2021, 26(1), 164-172.
[http://dx.doi.org/10.1016/j.drudis.2020.10.013 ] [PMID: 33099023]

Mathys, H.; Davila-Velderrain, J.; Peng, Z.; Gao, F.; Mohammadi, S.; Young, J.Z.; Menon, M.; He, L.; Abdurrob, F.; Jiang, X.; Martorell, A.J.; Ransohoff, R.M.; Hafler, B.P.; Bennett, D.A.; Kellis, M.; Tsai, L.H. Single-cell transcriptomic analysis of Alzheimer’s disease. Nature, 2019, 570(7761), 332-337.
[http://dx.doi.org/10.1038/s41586-019-1195-2 ] [PMID: 31042697]

He, Q.; Jiang, L.; Zhang, Y.; Yang, H.; Zhou, C.N.; Xie, Y.H.; Luo, Y.M.; Zhang, S.S.; Zhu, L.; Guo, Y.J.; Deng, Y.H.; Liang, X.; Xiao, Q.; Zhang, L.; Tang, J.; Huang, D.J.; Zhou, Y.N.; Dou, X.Y.; Chao, F.L.; Tang, Y. Anti-LINGO-1 antibody ameliorates cognitive impairment, promotes adult hippocampal neurogenesis, and increases the abundance of CB1R-rich CCK-GABAergic interneurons in AD mice. Neurobiol. Dis., 2021, 156, 105406.
[http://dx.doi.org/10.1016/j.nbd.2021.105406 ] [PMID: 34044148]

Xu, J.; Zhang, P.; Huang, Y.; Zhou, Y.; Hou, Y.; Bekris, L.M.; Lathia, J.; Chiang, C.W.; Li, L.; Pieper, A.A.; Leverenz, J.B.; Cummings, J.; Cheng, F. Multimodal single-cell/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer’s disease. Genome Res., 2021, 31(10), 1900-1912.
[http://dx.doi.org/10.1101/gr.272484.120 ] [PMID: 33627474]

Olah, M.; Menon, V.; Habib, N.; Taga, M.F.; Ma, Y.; Yung, C.J.; Cimpean, M.; Khairallah, A.; Corona, S.G.; Sankowski, R.; Grün, D.; Kroshilina, A.A.; Dionne, D.; Sarkis, R.A.; Cosgrove, G.R.; Helgager, J.; Golden, J.A.; Pennell, P.B.; Prinz, M.; Vonsattel, J.P.G.; Teich, A.F.; Schneider, J.A.; Bennett, D.A.; Regev, A.; Elyaman, W.; Bradshaw, E.M.; De Jager, P.L. Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer’s disease. Nat. Commun., 2020, 11(1), 6129.
[http://dx.doi.org/10.1038/s41467-020-19737-2 ] [PMID: 33257666]

Bordone, M.C.; Barbosa-Morais, N.L. Unraveling targetable systemic and cell-type-specific molecular phenotypes of Alzheimer’s and Parkinson’s brains with digital cytometry. Front. Neurosci., 2020, 14, 607215.
[http://dx.doi.org/10.3389/fnins.2020.607215 ] [PMID: 33362460]

Sim, N.L.; Kumar, P.; Hu, J.; Henikoff, S.; Schneider, G.; Ng, P.C. SIFT web server: Predicting effects of amino acid substitutions on proteins. Nucleic Acids Res., 2012, 40(W1), W452-W457.
[http://dx.doi.org/10.1093/nar/gks539 ] [PMID: 22689647]

Carter, H.; Douville, C.; Stenson, P.D.; Cooper, D.N.; Karchin, R. Identifying Mendelian disease genes with the variant effect scoring tool. BMC Genomics, 2013, 14(Suppl. 3), S3.
[http://dx.doi.org/10.1186/1471-2164-14-S3-S3 ] [PMID: 23819870]

Rentzsch, P.; Witten, D.; Cooper, G.M.; Shendure, J.; Kircher, M. CADD: Predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res., 2019, 47(D1), D886-D894.
[http://dx.doi.org/10.1093/nar/gky1016 ] [PMID: 30371827]

Rogers, M.F.; Shihab, H.A.; Mort, M.; Cooper, D.N.; Gaunt, T.R.; Campbell, C. FATHMM-XF: Accurate prediction of pathogenic point mutations via extended features. Bioinformatics, 2018, 34(3), 511-513.
[http://dx.doi.org/10.1093/bioinformatics/btx536 ] [PMID: 28968714]

Ferreira, K.C.V.; Fialho, L.F.; Franco, O.L.; De Alencar, S.A.; Porto, W.F. Benchmarking analysis of deleterious SNP prediction tools on CYP2D6 enzyme. Chem. Biol. Drug Des., 2020, 96(3), 984-994.
[http://dx.doi.org/10.1111/cbdd.13676 ] [PMID: 32149466]

Kulandaisamy, A.; Zaucha, J.; Sakthivel, R.; Frishman, D.; Michael Gromiha, M. Pred‐MutHTP: Prediction of disease‐causing and neutral mutations in human transmembrane proteins. Hum. Mutat., 2020, 41(3), 581-590.
[http://dx.doi.org/10.1002/humu.23961 ] [PMID: 31821684]

Capriotti, E.; Altman, R.B. A new disease-specific machine learning approach for the prediction of cancer-causing missense variants. Genomics, 2011, 98(4), 310-317.
[http://dx.doi.org/10.1016/j.ygeno.2011.06.010 ] [PMID: 21763417]

Shihab, H.A.; Gough, J.; Cooper, D.N.; Stenson, P.D.; Barker, G.L.A.; Edwards, K.J.; Day, I.N.M.; Gaunt, T.R. Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models. Hum. Mutat., 2013, 34(1), 57-65.
[http://dx.doi.org/10.1002/humu.22225 ] [PMID: 23033316]

Anoosha, P.; Sakthivel, R.; Michael Gromiha, M. Exploring preferred amino acid mutations in cancer genes: Applications to identify potential drug targets. Biochim. Biophys. Acta Mol. Basis Dis., 2016, 1862(2), 155-165.
[http://dx.doi.org/10.1016/j.bbadis.2015.11.006 ] [PMID: 26581171]

Tang, N.; Sandahl, T.D.; Ott, P.; Kepp, K.P. Computing the Pathogenicity of Wilson’s Disease ATP7B Mutations: Implications for disease prevalence. J. Chem. Inf. Model., 2019, 59(12), 5230-5243.
[http://dx.doi.org/10.1021/acs.jcim.9b00852 ] [PMID: 31751128]

Dorfman, R.; Nalpathamkalam, T.; Taylor, C.; Gonska, T.; Keenan, K.; Yuan, X.W.; Corey, M.; Tsui, L-C.; Zielenski, J.; Durie, P. Do common in silico tools predict the clinical consequences of amino-acid substitutions in the CFTR gene? Clin. Genet., 2010, 77(5), 464-473.
[http://dx.doi.org/10.1111/j.1399-0004.2009.01351.x] [PMID: 20059485]

Anoosha, P.; Huang, L.T.; Sakthivel, R.; Karunagaran, D.; Gromiha, M.M. Discrimination of driver and passenger mutations in epidermal growth factor receptor in cancer. Mutat. Res., 2015, 780, 24-34.
[http://dx.doi.org/10.1016/j.mrfmmm.2015.07.005] [PMID: 26264175]

Niroula, A.; Vihinen, M. Variation interpretation predictors: principles, types, performance, and choice. Hum. Mutat., 2016, 37(6), 579-597.
[http://dx.doi.org/10.1002/humu.22987 ] [PMID: 26987456]

Rangaswamy, U.; Dharshini, S.A.P.; Yesudhas, D.; Gromiha, M.M. VEPAD - Predicting the effect of variants associated with Alzheimer’s disease using machine learning. Comput. Biol. Med., 2020, 124, 103933.
[http://dx.doi.org/10.1016/j.compbiomed.2020.103933] [PMID: 32828070]

Kulandaisamy, A.; Parvathy Dharshini, S.A.; Gromiha, M.M. Alz-Disc: A tool to discriminate disease-causing and neutral mutations in Alzheimer’s disease. Comb. Chem. High Throughput Screen., 2022, 25. E-pub Ahead of Print]
[http://dx.doi.org/10.2174/1386207325666220520102316 ] [PMID: 35619290]

Lambert, J.C.; Ibrahim-Verbaas, C.A.; Harold, D.; Naj, A.C.; Sims, R.; Bellenguez, C.; Jun, G.; DeStefano, A.L.; Bis, J.C.; Beecham, G.W.; Grenier-Boley, B.; Russo, G.; Thornton-Wells, T.A.; Jones, N.; Smith, A.V.; Chouraki, V.; Thomas, C.; Ikram, M.A.; Zelenika, D.; Vardarajan, B.N.; Kamatani, Y.; Lin, C-F.; Gerrish, A.; Schmidt, H.; Kunkle, B.; Dunstan, M.L.; Ruiz, A.; Bihoreau, M-T.; Choi, S-H.; Reitz, C.; Pasquier, F.; Hollingworth, P.; Ramirez, A.; Hanon, O.; Fitzpatrick, A.L.; Buxbaum, J.D.; Campion, D.; Crane, P.K.; Baldwin, C.; Becker, T.; Gudnason, V.; Cruchaga, C.; Craig, D.; Amin, N.; Berr, C.; Lopez, O.L.; De Jager, P.L.; Deramecourt, V.; Johnston, J.A.; Evans, D.; Lovestone, S.; Letenneur, L.; Morón, F.J.; Rubinsztein, D.C.; Eiriksdottir, G.; Sleegers, K.; Goate, A.M.; Fiévet, N.; Huentelman, M.J.; Gill, M.; Brown, K.; Kamboh, M.I.; Keller, L.; Barberger-Gateau, P.; McGuinness, B.; Larson, E.B.; Green, R.; Myers, A.J.; Dufouil, C.; Todd, S.; Wallon, D.; Love, S.; Rogaeva, E.; Gallacher, J.; St George-Hyslop, P.; Clarimon, J.; Lleo, A.; Bayer, A.; Tsuang, D.W.; Yu, L.; Tsolaki, M.; Bossù, P.; Spalletta, G.; Proitsi, P.; Collinge, J.; Sorbi, S.; Sanchez-Garcia, F.; Fox, N.C.; Hardy, J.; Naranjo, M.C.D.; Bosco, P.; Clarke, R.; Brayne, C.; Galimberti, D.; Mancuso, M.; Matthews, F.; Moebus, S.; Mecocci, P.; Del Zompo, M.; Maier, W.; Hampel, H.; Pilotto, A.; Bullido, M.; Panza, F.; Caffarra, P.; Nacmias, B.; Gilbert, J.R.; Mayhaus, M.; Lannfelt, L.; Hakonarson, H.; Pichler, S.; Carrasquillo, M.M.; Ingelsson, M.; Beekly, D.; Alvarez, V.; Zou, F.; Valladares, O.; Younkin, S.G.; Coto, E.; Hamilton-Nelson, K.L.; Gu, W.; Razquin, C.; Pastor, P.; Mateo, I.; Owen, M.J.; Faber, K.M.; Jonsson, P.V.; Combarros, O.; O’Donovan, M.C.; Cantwell, L.B.; Soininen, H.; Blacker, D.; Mead, S.; Mosley, T.H., Jr; Bennett, D.A.; Harris, T.B.; Fratiglioni, L.; Holmes, C.; de Bruijn, R.F.A.G.; Passmore, P.; Montine, T.J.; Bettens, K.; Rotter, J.I.; Brice, A.; Morgan, K.; Foroud, T.M.; Kukull, W.A.; Hannequin, D.; Powell, J.F.; Nalls, M.A.; Ritchie, K.; Lunetta, K.L.; Kauwe, J.S.K.; Boerwinkle, E.; Riemenschneider, M.; Boada, M.; Hiltunen, M.; Martin, E.R.; Schmidt, R.; Rujescu, D.; Wang, L-S.; Dartigues, J-F.; Mayeux, R.; Tzourio, C.; Hofman, A.; Nöthen, M.M.; Graff, C.; Psaty, B.M.; Jones, L.; Haines, J.L.; Holmans, P.A.; Lathrop, M.; Pericak-Vance, M.A.; Launer, L.J.; Farrer, L.A.; van Duijn, C.M.; Van Broeckhoven, C.; Moskvina, V.; Seshadri, S.; Williams, J.; Schellenberg, G.D.; Amouyel, P. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat. Genet., 2013, 45(12), 1452-1458.
[http://dx.doi.org/10.1038/ng.2802 ] [PMID: 24162737]

Carithers, L.J.; Moore, H.M. The Genotype-Tissue Expression (GTEx) Project. Biopreserv. Biobank., 2015, 13(5), 307-308.
[http://dx.doi.org/10.1089/bio.2015.29031.hmm ] [PMID: 26484569]

Xu, Y.; Kong, J.; Hu, P. Computational Drug Repurposing for Alzheimer’s Disease Using Risk Genes From GWAS and Single-Cell RNA Sequencing Studies. Front. Pharmacol., 2021, 12, 617537.
[http://dx.doi.org/10.3389/fphar.2021.617537 ] [PMID: 34276354]

Fang, J.; Zhang, P.; Wang, Q.; Chiang, C.W.; Zhou, Y.; Hou, Y.; Xu, J.; Chen, R.; Zhang, B.; Lewis, S.J.; Leverenz, J.B.; Pieper, A.A.; Li, B.; Li, L.; Cummings, J.; Cheng, F. Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer’s disease. Alzheimers Res. Ther., 2022, 14(1), 7.
[http://dx.doi.org/10.1186/s13195-021-00951-z ] [PMID: 35012639]

Wu, A.T.H.; Lawal, B.; Wei, L.; Wen, Y.T.; Tzeng, D.T.W.; Lo, W.C. Multiomics identification of potential targets for Alzhemier’s disease and antrocin as a therapeutic candidate. Pharmaceutics, 2021, 13(10), 1555.
[http://dx.doi.org/10.3390/pharmaceutics13101555] [PMID: 34683848]

Stathias, V.; Turner, J.; Koleti, A.; Vidovic, D.; Cooper, D.; Fazel-Najafabadi, M.; Pilarczyk, M.; Terryn, R.; Chung, C.; Umeano, A.; Clarke, D.J.B.; Lachmann, A.; Evangelista, J.E.; Ma’ayan, A.; Medvedovic, M.; Schürer, S.C. LINCS Data Portal 2.0: Next generation access point for perturbation-response signatures. Nucleic Acids Res., 2020, 48(D1), D431-D439.
[http://dx.doi.org/10.1093/nar/gkz1023 ] [PMID: 31701147]

Kareti, S.R. P, S. In silico molecular docking analysis of potential anti-alzheimer’s compounds present in chloroform extract of Carissa carandas leaf using gas chromatography MS/MS. Curr. Ther. Res. Clin. Exp., 2020, 93, 100615.
[http://dx.doi.org/10.1016/j.curtheres.2020.100615] [PMID: 33306055]

Ponnulakshmi, R.; Sardar, H.; Vishnupriya, V.; Balakrishna, J.P.; Mohan, S.K.; Nivedha, R.P.; Vijayalakshmi, P.; Ponnulakshmi, R. Molecular docking analysis of amyloid precursor protein with compounds from the Australian cowplant. Bioinformation, 2020, 16(7), 561-566.
[http://dx.doi.org/10.6026/97320630016561 ] [PMID: 32994682]

Barale, S.S.; Parulekar, R.S.; Fandilolu, P.M.; Dhanavade, M.J.; Sonawane, K.D. Molecular insights into destabilization of Alzheimer’s aβ protofibril by arginine containing short peptides: A molecular modeling approach. ACS Omega, 2019, 4(1), 892-903.
[http://dx.doi.org/10.1021/acsomega.8b02672]

Melquiond, A.; Dong, X.; Mousseau, N.; Derreumaux, P. Role of the region 23-28 in Abeta fibril formation: Insights from simulations of the monomers and dimers of Alzheimer’s peptides Abeta40 and Abeta42. Curr. Alzheimer Res., 2008, 5(3), 244-250.
[http://dx.doi.org/10.2174/156720508784533330 ] [PMID: 18537541]

Khan, R.H.; Siddiqi, M.K.; Uversky, V.N.; Salahuddin, P. Molecular docking of Aβ1–40 peptide and its Iowa D23N mutant using small molecule inhibitors: Possible mechanisms of Aβ-peptide inhibition. Int. J. Biol. Macromol., 2019, 127, 250-270.
[http://dx.doi.org/10.1016/j.ijbiomac.2018.12.271] [PMID: 30615966]

Hassan, M.; Shahzadi, S.; Seo, S.Y.; Alashwal, H.; Zaki, N.; Moustafa, A.A. Molecular docking and dynamic simulation of AZD3293 and solanezumab effects against bace1 to treat alzheimer’s disease. Front. Comput. Neurosci., 2018, 12, 34.
[http://dx.doi.org/10.3389/fncom.2018.00034 ] [PMID: 29910719]

Gosoi, D.; Saikia, R.; Kalita, J.; Paul, R.; Pegu, D.K.; Sinha, S.; Johari, S. Combining virtual screening, molecular docking and simulation studies towards the discovery of β-Secretase (BACE) inhibitors. Int. Conf. Bioinforma. Syst. Biol. BSB 2018, 2018, pp. 103-107.
[http://dx.doi.org/10.1109/BSB.2018.8770645]

Kumar, A.; Roy, S.; Tripathi, S.; Sharma, A. Molecular docking based virtual screening of natural compounds as potential BACE1 inhibitors: 3D QSAR pharmacophore mapping and molecular dynamics analysis. J. Biomol. Struct. Dyn., 2016, 34(2), 239-249.
[http://dx.doi.org/10.1080/07391102.2015.1022603] [PMID: 25707809]

Pradeepkiran, J.; Reddy, P. Structure based design and molecular docking studies for phosphorylated tau inhibitors in Alzheimer’s disease. Cells, 2019, 8(3), 260.
[http://dx.doi.org/10.3390/cells8030260 ] [PMID: 30893872]

Sato, R.; Vohra, S.; Yamamoto, S.; Suzuki, K.; Pavel, K.; Shulga, S.; Blume, Y.; Kurita, N. Specific interactions between tau protein and curcumin derivatives: Molecular docking and ab initio molecular orbital simulations. J. Mol. Graph. Model., 2020, 98, 107611.
[http://dx.doi.org/10.1016/j.jmgm.2020.107611] [PMID: 32276176]

Barredo, P.A.; Fernandez, M.J.F.; Ambe, C.E.; Balanay, M.P. Tau fibril with membrane lipids: Insight from computational modeling and simulations. PLoS One, 2021, 16(10), e0258692.
[http://dx.doi.org/10.1371/journal.pone.0258692 ] [PMID: 34653235]